F-1/A: NewGenIvf Shifts to Profit Amid Strategic Diversification

NewGenIvf Group Limited reported a net income for H1 2025, driven by a bargain purchase gain and capital raises, while expanding into digital assets and UAE real estate.

Summary

• NewGenIvf Group Limited is an assisted reproductive services (ARS) provider operating in Thailand, Cambodia, and Kyrgyzstan, offering IVF, egg donation, and surrogacy services.
• The company reported a net income of $698,032 for the six months ended June 30, 2025, a significant improvement from a net loss of $387,781 in the same period of 2024.
• Revenue for H1 2025 decreased to $2,019,628 from $2,686,902 in H1 2024, primarily due to a temporary cessation of surrogacy services in Kyrgyzstan in 2024.
• Operating expenses surged by 283.5% to $3,554,180 in H1 2025 from $926,618 in H1 2024, leading to a substantial operating loss of $3,240,376.
• A significant 'Other income, net' of $4,062,303 in H1 2025, including a $19.2 million bargain purchase gain from the MicroSort technology acquisition, was the primary driver of the net income.
• The company successfully regained compliance with Nasdaq's minimum bid price rule and transferred its listing to the Nasdaq Capital Market in February 2025, following multiple reverse stock splits.
• NewGenIvf is pursuing strategic investments in digital assets, planning to stake up to $30 million in SOL tokens, and has accumulated 13,000.23 SOL tokens valued at approximately $2.94 million as of October 8, 2025.
• A joint venture agreement was signed on October 6, 2025, with BNW Real Estate Development LLC to develop a strategic plot of land in Ras Al Khaimah's Beach District, UAE, with NewGenProperty holding a 60% stake.
• The company secured new debt financing, including a $3.2 million senior convertible note on April 1, 2025, and an additional $2 million note on April 2, 2025, with further potential for $25.6 million in additional notes.
• An equity line of credit with White Lion Capital, LLC provides access to up to $100 million, expandable to $500 million, with $11.66 million already drawn by August 5, 2025.

Sentiment

Score: 6

Explanation: The company shows significant financial improvement in H1 2025, driven by a large non-operating gain and successful capital raises, and has resolved Nasdaq compliance issues. However, core operating revenue declined, operating losses increased, and significant legal and regulatory risks remain, particularly concerning management and gender selection services. Diversification into digital assets and real estate introduces new, high-risk ventures.

Positives

• Achieved net income of $698,032 in H1 2025, a significant turnaround from a net loss of $387,781 in H1 2024.
• Shareholders' equity dramatically improved from a deficit of $1,481,757 as of December 31, 2024, to a positive $8,789,154 as of June 30, 2025.
• Successfully regained compliance with Nasdaq listing requirements, including the minimum bid price rule, and transferred to the Nasdaq Capital Market.
• Completed the acquisition of MicroSort technology, exclusively owning pre-conception gender selection technology, which is valued at $17.9 million and resulted in a $19.2 million bargain purchase gain.
• Initiated a strategic investment in digital assets (SOL staking) with plans for up to $30 million, showing diversification and potential for new revenue streams.
• Entered into a joint venture for real estate development in the UAE, expanding business into a new sector.
• Secured significant capital through new convertible notes ($3.2 million initial tranche, $2 million additional note, potential for $25.6 million more) and an equity line of credit with White Lion Capital (up to $500 million).
• Gross profit margin slightly increased from 32.7% in 2023 to 33.6% in 2024, attributed to cooperation model reorganization and marketing efficiency.

Negatives

• Revenue for H1 2025 decreased by 24.8% compared to H1 2024, primarily due to the temporary cessation of surrogacy services in Kyrgyzstan.
• Operating expenses increased significantly by 283.5% in H1 2025, leading to a substantial operating loss of $3,240,376.
• The company had an accumulated deficit of $985,994 as of December 31, 2024, and a net loss of $474,101 for the full year 2024.
• The company faces substantial doubt about its ability to continue as a going concern as of December 31, 2024, despite recent capital raises.
• CEO and CMO were arrested in Hong Kong on April 25, 2025, for alleged violations of the Human Reproductive Technology Ordinance (HRTO) related to gender selection advertising, with charges expected in mid-October 2025.
• The dual-class voting structure concentrates significant control (16.04% of voting power) in the hands of the CEO and CMO, potentially limiting influence for Class A shareholders.
• The company terminated a proposed reverse merger with European Wellness Investment Holdings Limited (EWIHL) due to EWIHL's failure to provide audited financials.
• Reliance on international clients, particularly from China, exposes the company to geopolitical risks, economic conditions, and travel restrictions, as seen with the impact of COVID-19 and negative media coverage.

Risks

• Inability to continue operating as a going concern due to potential financial and liquidity shortfalls.
• Highly competitive fertility market, with more established competitors having greater resources and brand recognition.
• Limited operating history with current platform, making future financial performance difficult to predict.
• Solana digital asset staking strategy is subject to extreme price volatility of SOL, staking and liquidity risks (unbonding periods), operational and validator risks, custodial and security risks, and regulatory uncertainty.
• Investment in the UAE residential real estate market is exposed to significant market volatility, potential oversupply, and sensitivity to oil prices, global economic conditions, and regional geopolitics.
• Dependence on positive client references for marketing efforts; loss or dissatisfaction of clients could harm brand and reputation.
• Failure to attract new clients or maintain existing client demographics could adversely affect business and financial results.
• Inability to successfully manage growth, leading to reduced client satisfaction and lower revenue growth.
• Failure to innovate and develop new solutions or adapt to changing medical landscapes and regulations could make offerings less competitive.
• Loss of key management team members or inability to attract qualified personnel could harm business and growth prospects.
• Exposure to international business risks in Asia-Pacific markets, including economic conditions, exchange rate fluctuations, and governmental control of currency conversion.
• Ethical, legal, and social concerns related to assisted reproductive technology could reduce demand for services.
• Failure to comply with filing deadlines for SEC reports, potentially leading to enforcement actions, delisting, or breach of credit covenants.
• Medical facilities and professionals in the network could become subject to litigation, allegations, and claims, with no insurance coverage for operations.
• Limited control over the quality of pharmaceuticals, medical equipment, and supplies from third-party suppliers, and no control over independent sub-contractors.
• Potential loss of relationships with one or more key pharmaceutical manufacturers.
• Related party transactions present potential conflicts of interest.
• Claims and allegations relating to intellectual property infringement or other causes.
• Reliance on third-party data and polls for market estimates, which may not be accurate.
• Operating in a highly regulated industry with complex and evolving requirements; any lack of requisite approvals, licenses, or permits could have a material adverse impact.
• Advertising or offering of gender selection services in certain jurisdictions (e.g., Hong Kong) could expose the company and its directors/executive officers to significant legal and regulatory risks and potential penalties.
• Changes in effective tax rate or tax liability could adversely affect results of operations.
• Adverse effects from changes in U.S. GAAP accounting principles or incorrect estimates/judgments in critical accounting policies.
• Non-compliance with anti-corruption, anti-bribery, anti-money laundering, and similar laws.
• Significant tariffs or other restrictions imposed on imports by the U.S. and related countermeasures by impacted countries could affect operations and financial results.
• Litigation against the company could be costly and time-consuming to defend and could harm its business, financial condition, and results of operations.
• Acquisitions, strategic investments, partnerships, or alliances could pose integration challenges, divert management attention, dilute stockholder value, and adversely affect business, financial condition, and results of operations.

Future Outlook

NewGenIvf aims to provide tailored ARS solutions and expand its market share in Asia-Pacific by offering broad fertility services for fertility tourists, continuing to invest in laboratories and facilities, increasing brand awareness through social media and partnerships, and expanding service reach through strategic acquisitions and partnerships. The company plans to integrate hospitality services for traveling patients and develop advanced facilities for ARS research to improve success rates and lower costs. It also intends to explore offering fertility services as part of corporate benefit programs and establish a home country gynecologist partnership program. The company plans to systematically deploy up to $30 million in staking SOL digital assets over 18 months and is developing a real estate project in the UAE.

Management Comments

• Management believes that its competitive strengths, including broad-range ARS offerings, attractive market positioning, exclusively owned MicroSort technology, established brand, and experienced team, position it to meet growing opportunities in the Asia-Pacific fertility market.
• Management is closely monitoring the market for opportunities and carrying out various fundraising projects to improve cash flow and address the substantial doubt about its ability to continue as a going concern.
• Management believes that if recovery of the PRC economy is sustainable, it might increase the demand for NewGenIvf's services and therefore in turn affect its results of operations.
• Management believes that using an incremental borrowing rate of the minimum loan rate and Hong Kong Dollar Best Lending Rate (BLR) minus 0.125% was the most indicative rate of the company's borrowing cost for the calculation of the present value of the lease payments.

Industry Context

The Asia-Pacific assisted reproductive services (ARS) market is experiencing significant growth, driven by a rising number of women in the key ARS-targeted age group, a growing trend towards later maternal age, increasing social acceptance of ARS, and a substantial prevalence of infertility (e.g., Thailand 15.4%, India 13.8%, China 17.8% in 2022). The market is projected to reach US$37.4 billion by 2030. NewGenIvf's strategic presence in Thailand, Cambodia, and Kyrgyzstan, coupled with its comprehensive service offerings and MicroSort technology, positions it to capitalize on fertility tourism and unmet demand. However, the industry faces challenges such as financial costs, limited access to care, and regulatory complexities. The company's diversification into digital assets and real estate is a departure from its core ARS industry, introducing new market dynamics and risks.

Comparison to Industry Standards

• NewGenIvf's average cost per IVF cycle is around US$7,000 (excluding medication), which is presented as 'relatively low cost' compared to the US market, suggesting a competitive pricing strategy for fertility tourism.
• The company's reported IVF implantation rate of 70.9% and miscarriage rate reduction by 26.6% (with PGS) are presented as 'improved clinical outcomes' compared to an industry average clinical pregnancy success rate of approximately 64.6% (with no PGT) and live birth rate of 28.7% for 5-day incubation IVF, as cited by CIC. This suggests superior clinical efficacy in specific areas.
• NewGenIvf is noted as 'one of the few ARS providers in Kyrgyzstan and one of the few companies in Kyrgyzstan that is licensed to offer surrogacy services,' indicating a strong competitive position in that specific niche market.
• The company's strategy to offer 'hassle-free, seamless and integrated ARS and hospitality arrangement experience' for fertility tourists aims to differentiate it from competitors by addressing broader patient needs beyond medical treatment, potentially setting a higher service standard in the region.

Management Changes

Corporate Governance

Legal Proceedings

• Wing Fung Alfred Siu (CEO) and Hei Yue Tina Fong (CMO) were arrested in Hong Kong on April 25, 2025, for allegedly violating sections 15A(1) and 17(2) of the Human Reproductive Technology Ordinance (HRTO), which prohibit using reproductive technologies for sex selection, advertising sex selection services, commercial surrogacy arrangements, and advertising surrogacy arrangements.
• All persons arrested have been released on a bail amount of HKD 3,000 ($390), and no charges have been brought against the company or any of its other officers, directors, or employees as of the date of this prospectus.
• Charges are expected to be brought against Wing Fung Alfred Siu and Hei Yue Tina Fong in mid-October 2025, with a court hearing potentially convened shortly thereafter.
• If convicted, each person could face a fine of up to HKD 25,000 (approximately $3,200) and imprisonment for up to 6 months. A custodial sentence for the CEO could materially impact the business.
• The company does not expect to be materially impacted by increased enforcement of the HRTO as it does not advertise or promote gender selection services in Hong Kong, and PRC-sourced revenues are generated through referrals from PRC agents with direct payments to local clinics. However, regulatory scrutiny could still lead to adverse publicity and increased compliance costs.

Related Party Transactions

• As of June 30, 2025, amounts due from Mr. Siu, Wing Fung Alfred (CEO), Ms. Fong, Hei Yue Tina (CMO), and Harcourt Limited (controlled by Mr. Siu) totaled $382,687, which is expected to be repaid before the end of 2025.
• Remuneration paid to Mr. Siu, Wing Fung Alfred was $190,000 in 2024 and $120,000 in H1 2025.
• Remuneration paid to Ms. Fong, Hei Yue Tina was $190,000 in 2024 and $120,000 in H1 2025.
• Mr. Siu Wing Fung Alfred also received a directors bonus of $750,000 in H1 2025.
• In 2023, Mr. Siu Wing Fung Alfred waived a balance of $88,151 due from the company.

Stakeholder Impact

• Shareholders: Potential for significant dilution from the resale of up to 50,000,000 Class A Ordinary Shares by selling securityholders, which represents a substantial percentage of outstanding shares. The dual-class voting structure limits the influence of Class A shareholders. However, the recent increase in shareholders' equity and net income in H1 2025, driven by non-operating gains, could be positive for investor sentiment, while ongoing legal proceedings against management pose reputational and operational risks.
• Employees: The company's growth strategies and investments in laboratories and facilities could create new opportunities. The amended Share Incentive Plan aims to attract and retain key personnel. However, potential delisting risks and financial uncertainties could impact employee morale and retention.
• Customers: Expansion of services, investment in advanced technologies (MicroSort, PGS, NGS, PGD), and plans for integrated hospitality services aim to enhance customer experience and success rates. The 'success guarantee program' for certain services offers added value. However, temporary cessation of surrogacy services in Kyrgyzstan and potential negative publicity from legal issues could affect customer trust.
• Suppliers: Increased procurement needs due to expansion could benefit suppliers. However, the company's focus on cost-effective supplies and reliable suppliers indicates a disciplined approach to procurement.
• Creditors: The company's ability to raise significant capital through convertible notes and an equity line of credit, along with improved shareholders' equity, may enhance its creditworthiness. However, the 'going concern' doubt and increased total liabilities require careful monitoring.

Next Steps

• Systematically deploy the remaining capital (approximately $28.76 million) to acquire SOL using a dollar-cost averaging methodology over Q3 2025 Q4 2026.
• Evaluate various validators and establish validator relationships to begin staking SOL, intending to stake a majority of SOL holdings.
• Actively manage validator relationships and reward optimization for SOL staking (ongoing Phase 3).
• Negotiate and execute a definitive Joint Venture Agreement with BNW Real Estate Development LLC for the UAE real estate project.
• Develop advanced facilities for existing laboratories, conducting research on ARS basic science and emerging technologies.
• Correlate patient treatment protocols data to embryo physiologic data and pregnancy success rate data to identify better treatment protocols.
• Actively promote technological cooperation with tertiary institutions to improve IVF success rates.
• Deploy existing technology to expand services, including treatments for patients over 40 with premature ovarian failure and recurrent ARS implementation failure.
• Implement technological advancements such as microfluidics, automated sperm analysers, time-lapsed incubators, non-invasive PGT, automated oocyte/embryo vitrification, and mitochondria replacement therapy.
• Develop clinically customized interior design concepts for medical facilities, including improved service rooms, consultation rooms, reception areas, nutrition food areas, and traditional Chinese medicine facilities.
• Collaborate with local hospitals, companies, premium hospitality providers, and other key players in the ARS industry in Asia Pacific to expand reach and increase patient numbers.
• Increase brand awareness through social media promotions and marketing initiatives, and establish a business development team.
• Introduce innovative treatment services, such as IVF mental health services, to attract more clients.
• Expand service reach through strategic acquisitions and/or partnerships in Asia Pacific, focusing on ARS providers with conventional licenses and recognized brands.
• Explore expanding client base by offering fertility services as part of corporate benefit programs in Asia.
• Establish a home country gynecologist partnership program to offer treatment services with reduced overseas time requirements.
• Wing Fung Alfred Siu and Hei Yue Tina Fong are expected to face charges in mid-October 2025, followed by a court hearing shortly thereafter, regarding alleged HRTO violations.

Key Dates

Recommendation

NewGenIvf has demonstrated a significant financial turnaround in H1 2025, moving from a net loss to a net income, largely due to a substantial bargain purchase gain from the MicroSort technology acquisition and successful capital raises. The company has also resolved its Nasdaq listing compliance issues, which is a positive for market stability. Strategic diversification into digital assets and UAE real estate offers potential long-term growth avenues. However, core operating revenue declined, and operating expenses surged, indicating underlying operational challenges. The 'going concern' doubt, while mitigated by recent financing, persists as a fundamental risk. Furthermore, the legal proceedings against the CEO and CMO, although not directly against the company, introduce reputational and leadership uncertainty. Given these mixed signals – strong non-operating gains and strategic initiatives balanced against operational weaknesses and significant legal/regulatory risks – a 'hold' recommendation is appropriate. Investors should monitor the execution of new strategies, resolution of legal matters, and sustained improvement in core operating performance before considering further investment.

Keywords

Assisted Reproductive Services, IVF, Fertility Treatment, MicroSort Technology, Surrogacy, Egg Freezing, Asia-Pacific Healthcare, Nasdaq Capital Market, Digital Assets, Solana Staking, UAE Real Estate, SEC Filing, F-1/A, Capital Raise, Corporate Governance, Risk Management, Financial Performance